ÇETİN, GÜVENEŞKAZAN, Ahmet EmreAR, Muhlis CemAydin, Seniz OngorenFerhanoglu, BurhanSoysal, TeomanBaslar, ZaferAydin, Yildiz2020-10-222020-10-222014-12-01ÇETİN G., EŞKAZAN A. E. , AR M. C. , Aydin S. O. , Ferhanoglu B., Soysal T., Baslar Z., Aydin Y., -Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options-, TURKISH JOURNAL OF HEMATOLOGY, cilt.31, ss.374-380, 2014http://hdl.handle.net/20.500.12645/24654http://www.journalagent.com/z4/vi.asp?pdir=tjh&plng=eng&un=TJH-38159Objective: This study aimed to investigate the impact of the different therapy regimens used in multiple myeloma (MM) on bone-specific alkaline phosphatase (BALP) levels. Materials and Methods: One hundred and thirteen patients with MM were included in the study. Patients were grouped according to the regimens they received, as follows: group 1, melphalan and prednisolone (MP); group 2, vincristine, adriablastin, and dexamethasone (VAD); group 3, thalidomide plus dexamethasone; and group 4, bortezomib plus dexamethasone. BALP levels were measured before treatment and at the third and sixth months of treatment. A fifth group consisted of patients in the post-treatment remission period at study entry (no-treatment group). Results: The BALP levels at the third and sixth months of the treatment were significantly higher than the pre-treatment levels in the bortezomib and the no-treatment groups, whereas no significant difference was observed in the MP, VAD, and thalidomide groups. Conclusion: Considering that BALP is a surrogate marker of bone formation, our study suggests efficiently leads to the improvement of bone disease in myeloma than other treatment options.Multiple myelomaArticleWOS:0003486888000068492457389710.4274/tjh.2013.000425541654